Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 682

1.

18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab.

Lim I, Lindenberg ML, Mena E, Verdini N, Shih JH, Mayfield C, Thompson R, Lin J, Vega A, Mallek M, Cadena J, Diaz C, Mortazavi A, Knopp M, Wright C, Stein M, Pal S, Choyke PL, Apolo AB.

Eur J Nucl Med Mol Imaging. 2019 Sep 14. doi: 10.1007/s00259-019-04483-5. [Epub ahead of print]

PMID:
31522271
2.

A multiparametric magnetic resonance imaging-based virtual reality surgical navigation tool for robotic-assisted radical prostatectomy.

Mehralivand S, Kolagunda A, Hammerich K, Sabarwal V, Harmon S, Sanford T, Gold S, Hale G, Romero VV, Bloom J, Merino MJ, Wood BJ, Kambhamettu C, Choyke PL, Pinto PA, Türkbey B.

Turk J Urol. 2019 Sep 1;45(5):357-365. doi: 10.5152/tud.2019.19133.

3.

The Effect of Antibody Fragments on CD25 Targeted Regulatory T Cell Near Infrared Photoimmunotherapy (NIR-PIT).

Okada R, Maruoka Y, Furusawa A, Inagaki F, Nagaya T, Fujimura D, Choyke PL, Kobayashi H.

Bioconjug Chem. 2019 Sep 9. doi: 10.1021/acs.bioconjchem.9b00547. [Epub ahead of print]

PMID:
31498995
4.

Near-Infrared Photoimmunotherapy: Photoactivatable Antibody-Drug Conjugates (ADCs).

Kobayashi H, Griffiths GL, Choyke PL.

Bioconjug Chem. 2019 Sep 13. doi: 10.1021/acs.bioconjchem.9b00546. [Epub ahead of print]

PMID:
31479610
5.

Apical periurethral transition zone lesions: MRI and histology findings.

Tuncer S, Mehralivand S, Harmon SA, Sanford T, Brown GT, Rowe LS, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B.

Abdom Radiol (NY). 2019 Aug 29. doi: 10.1007/s00261-019-02194-x. [Epub ahead of print]

PMID:
31468153
6.

In Vitro Performance of Published Glypican 3-Targeting Peptides TJ12P1 and L5 Indicates Lack of Specificity and Potency.

Berman RM, Kelada OJ, Gutsche NT, Natarajan R, Swenson RE, Fu Y, Hong J, Ho M, Choyke PL, Escorcia FE.

Cancer Biother Radiopharm. 2019 Aug 19. doi: 10.1089/cbr.2019.2888. [Epub ahead of print]

PMID:
31424293
7.

Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice.

Kishimoto S, Brender JR, Crooks DR, Matsumoto S, Seki T, Oshima N, Merkle H, Lin P, Reed G, Chen AP, Ardenkjaer-Larsen JH, Munasinghe J, Saito K, Yamamoto K, Choyke PL, Mitchell J, Lane AN, Fan TW, Linehan WM, Krishna MC.

Elife. 2019 Aug 13;8. pii: e46312. doi: 10.7554/eLife.46312.

8.

Near-Infrared Photoimmunotherapy of Cancer.

Kobayashi H, Choyke PL.

Acc Chem Res. 2019 Aug 20;52(8):2332-2339. doi: 10.1021/acs.accounts.9b00273. Epub 2019 Jul 23.

9.

Lymph node involvement in treatment-naïve prostate cancer patients - correlation of PSMA-PET/CT imaging and Roach formula in 280 men in the Radiotherapeutic management.

Koerber SA, Stach G, Kratochwil C, Haefner MF, Rathke H, Herfarth K, Kopka K, Holland-Letz T, Choyke PL, Will L, Haberkorn U, Debus J, Giesel FL.

J Nucl Med. 2019 Jul 13. pii: jnumed.119.227637. doi: 10.2967/jnumed.119.227637. [Epub ahead of print]

PMID:
31302638
10.

Fluorine-18 Labeled Fluorofuranylnorprogesterone ([18F]FFNP) and Dihydrotestosterone ([18F]FDHT) Prepared by "Fluorination on Sep-Pak" Method.

Basuli F, Zhang X, Blackman B, White ME, Jagoda EM, Choyke PL, Swenson RE.

Molecules. 2019 Jun 28;24(13). pii: E2389. doi: 10.3390/molecules24132389.

11.

PI-RADS version 2.1: one small step for prostate MRI.

Barrett T, Rajesh A, Rosenkrantz AB, Choyke PL, Turkbey B.

Clin Radiol. 2019 Jun 22. pii: S0009-9260(19)30259-4. doi: 10.1016/j.crad.2019.05.019. [Epub ahead of print] Review.

PMID:
31239107
12.

New Targets for PET Molecular Imaging of Prostate Cancer.

Mena E, Lindenberg LM, Choyke PL.

Semin Nucl Med. 2019 Jul;49(4):326-336. doi: 10.1053/j.semnuclmed.2019.02.001. Epub 2019 Mar 9. Review.

PMID:
31227055
13.

Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer.

Roth AR, Harmon SA, Perk TG, Eickhoff J, Choyke PL, Kurdziel KA, Dahut WL, Apolo AB, Morris MJ, Perlman SB, Liu G, Jeraj R.

Clin Genitourin Cancer. 2019 Aug;17(4):306-314. doi: 10.1016/j.clgc.2019.05.013. Epub 2019 May 27.

PMID:
31221545
14.

Use of multiparametric magnetic resonance imaging and fusion-guided biopsies to properly select and follow African-American men on active surveillance.

Bloom JB, Lebastchi AH, Gold SA, Hale GR, Sanford T, Mehralivand S, Ahdoot M, Rayn KN, Czarniecki M, Smith C, Valera V, Wood BJ, Merino MJ, Choyke PL, Parnes HL, Turkbey B, Pinto PA.

BJU Int. 2019 May 29. doi: 10.1111/bju.14835. [Epub ahead of print]

PMID:
31141307
15.

Artificial intelligence at the intersection of pathology and radiology in prostate cancer.

Harmon SA, Tuncer S, Sanford T, Choyke PL, Türkbey B.

Diagn Interv Radiol. 2019 May;25(3):183-188. doi: 10.5152/dir.2019.19125.

16.

Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.

Jagoda EM, Vasalatiy O, Basuli F, Opina ACL, Williams MR, Wong K, Lane KC, Adler S, Ton AT, Szajek LP, Xu B, Butcher D, Edmondson EF, Swenson RE, Greiner J, Gulley J, Eary J, Choyke PL.

Mol Imaging. 2019 Jan-Dec;18:1536012119829986. doi: 10.1177/1536012119829986.

17.

mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy.

Gold SA, VanderWeele DJ, Harmon S, Bloom JB, Karzai F, Hale GR, Marhamati S, Rayn KN, Mehralivand S, Merino MJ, Gulley JL, Bilusic M, Madan RA, Choyke PL, Turkbey B, Dahut W, Pinto PA.

Urol Oncol. 2019 Jun;37(6):352.e25-352.e30. doi: 10.1016/j.urolonc.2019.01.012. Epub 2019 Apr 15.

PMID:
31000430
18.

Interreader Variability of Prostate Imaging Reporting and Data System Version 2 in Detecting and Assessing Prostate Cancer Lesions at Prostate MRI.

Greer MD, Shih JH, Lay N, Barrett T, Bittencourt L, Borofsky S, Kabakus I, Law YM, Marko J, Shebel H, Merino MJ, Wood BJ, Pinto PA, Summers RM, Choyke PL, Turkbey B.

AJR Am J Roentgenol. 2019 Mar 27:1-8. doi: 10.2214/AJR.18.20536. [Epub ahead of print]

PMID:
30917023
19.

First-in-human phase 0 study of 111In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging.

Kurdziel KA, Mena E, McKinney Y, Wong K, Adler S, Sissung T, Lee J, Lipkowitz S, Lindenberg L, Turkbey B, Kummar S, Milenic DE, Doroshow JH, Figg WD, Merino MJ, Paik CH, Brechbiel MW, Choyke PL.

J Transl Sci. 2019 Apr;5(2). doi: 10.15761/JTS.1000269. Epub 2018 Jul 13.

20.

Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.

Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, Tempany CM, Choyke PL, Cornud F, Margolis DJ, Thoeny HC, Verma S, Barentsz J, Weinreb JC.

Eur Urol. 2019 Sep;76(3):340-351. doi: 10.1016/j.eururo.2019.02.033. Epub 2019 Mar 18. Review.

PMID:
30898406
21.

Prostate Imaging Reporting and Data System Version 2 for MRI of Prostate Cancer: Can We Do Better?

Sackett J, Choyke PL, Turkbey B.

AJR Am J Roentgenol. 2019 Mar 19:1-9. doi: 10.2214/AJR.19.21178. [Epub ahead of print]

PMID:
30888865
22.

Prostate cancer detection from multi-institution multiparametric MRIs using deep convolutional neural networks.

Sumathipala Y, Lay N, Turkbey B, Smith C, Choyke PL, Summers RM.

J Med Imaging (Bellingham). 2018 Oct;5(4):044507. doi: 10.1117/1.JMI.5.4.044507. Epub 2018 Dec 15.

PMID:
30840728
23.

Novel Imaging in Detection of Metastatic Prostate Cancer.

Smith CP, Laucis A, Harmon S, Mena E, Lindenberg L, Choyke PL, Turkbey B.

Curr Oncol Rep. 2019 Mar 5;21(4):31. doi: 10.1007/s11912-019-0780-8. Review.

PMID:
30834999
24.

Dynamic Imaging of Glucose and Lactate Metabolism by 13C-MRS without Hyperpolarization.

Brender JR, Kishimoto S, Merkle H, Reed G, Hurd RE, Chen AP, Ardenkjaer-Larsen JH, Munasinghe J, Saito K, Seki T, Oshima N, Yamamoto K, Choyke PL, Mitchell J, Krishna MC.

Sci Rep. 2019 Mar 4;9(1):3410. doi: 10.1038/s41598-019-38981-1.

25.

The Distribution Volume of 18F-Albumin as a Potential Biomarker of Antiangiogenic Treatment Efficacy.

Roy J, Kuo F, Basuli F, Williams MR, Wong K, Green MV, Seidel J, Adler SS, Xu B, Choyke PL, Jagoda EM.

Cancer Biother Radiopharm. 2019 May;34(4):238-244. doi: 10.1089/cbr.2018.2656. Epub 2019 Feb 15.

PMID:
30767667
26.

Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT).

Siddiqui MR, Railkar R, Sanford T, Crooks DR, Eckhaus MA, Haines D, Choyke PL, Kobayashi H, Agarwal PK.

Sci Rep. 2019 Feb 14;9(1):2084. doi: 10.1038/s41598-019-38575-x.

27.

PET imaging in renal cancer.

Lindenberg L, Mena E, Choyke PL, Bouchelouche K.

Curr Opin Oncol. 2019 May;31(3):216-221. doi: 10.1097/CCO.0000000000000518.

PMID:
30747736
28.

A comparison of prostate cancer bone metastases on 18F-Sodium Fluoride and Prostate Specific Membrane Antigen (18F-PSMA) PET/CT: Discordant uptake in the same lesion.

Harmon SA, Mena E, Shih JH, Adler S, McKinney Y, Bergvall E, Mehralivand S, Sowalsky AG, Couvillon A, Madan RA, Gulley JL, Eary J, Mease RC, Pomper MG, Dahut WL, Turkbey B, Lindenberg L, Choyke PL.

Oncotarget. 2018 Dec 28;9(102):37676-37688. doi: 10.18632/oncotarget.26481. eCollection 2018 Dec 28.

29.

Prostate Magnetic Resonance Imaging: Lesion Detection and Local Staging.

Turkbey B, Choyke PL.

Annu Rev Med. 2019 Jan 27;70:451-459. doi: 10.1146/annurev-med-053117-123215.

PMID:
30691375
30.

Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors.

Nagaya T, Friedman J, Maruoka Y, Ogata F, Okuyama S, Clavijo PE, Choyke PL, Allen C, Kobayashi H.

Cancer Immunol Res. 2019 Mar;7(3):401-413. doi: 10.1158/2326-6066.CIR-18-0546. Epub 2019 Jan 25.

PMID:
30683733
31.

When to Biopsy the Seminal Vesicles: A Validated Multiparametric Magnetic Resonance Imaging and Target Driven Model to Detect Seminal Vesicle Invasion in Prostate Cancer.

Gold SA, Shih JH, Rais-Bahrami S, Bloom JB, Vourganti S, Singla N, Baroni RH, Coker MA, Fialkoff J, Noschang J, Roehrborn CG, Turkbey B, Pinto PA; Collaborators.

J Urol. 2019 Jan 23. doi: 10.1097/JU.0000000000000112. [Epub ahead of print]

PMID:
30681511
32.

Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project.

van Luijtelaar A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, Frauscher F, George AK, Hindley RG, Jenniskens SFM, Klotz L, Kovacs G, Lindner U, Loeb S, Margolis DJ, Marks LS, May S, Mcclure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, Reijnen JS, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Walser EM, Ward JF, Villers A, Ghai S, Fütterer JJ.

World J Urol. 2019 Jan 22. doi: 10.1007/s00345-019-02636-7. [Epub ahead of print]

33.

A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI.

Mehralivand S, Shih JH, Harmon S, Smith C, Bloom J, Czarniecki M, Gold S, Hale G, Rayn K, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B.

Radiology. 2019 Mar;290(3):709-719. doi: 10.1148/radiol.2018181278. Epub 2019 Jan 22.

PMID:
30667329
34.

Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.

Bloom JB, Hale GR, Gold SA, Rayn KN, Smith C, Mehralivand S, Czarniecki M, Valera V, Wood BJ, Merino MJ, Choyke PL, Parnes HL, Turkbey B, Pinto PA.

J Urol. 2019 Jan;201(1):84-90. doi: 10.1016/j.juro.2018.07.051.

PMID:
30577395
35.

Intra- and interreader reproducibility of PI-RADSv2: A multireader study.

Smith CP, Harmon SA, Barrett T, Bittencourt LK, Law YM, Shebel H, An JY, Czarniecki M, Mehralivand S, Coskun M, Wood BJ, Pinto PA, Shih JH, Choyke PL, Turkbey B.

J Magn Reson Imaging. 2019 Jun;49(6):1694-1703. doi: 10.1002/jmri.26555. Epub 2018 Dec 21.

PMID:
30575184
36.

Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy.

Sato K, Ando K, Okuyama S, Moriguchi S, Ogura T, Totoki S, Hanaoka H, Nagaya T, Kokawa R, Takakura H, Nishimura M, Hasegawa Y, Choyke PL, Ogawa M, Kobayashi H.

ACS Cent Sci. 2018 Nov 28;4(11):1559-1569. doi: 10.1021/acscentsci.8b00565. Epub 2018 Nov 6.

37.

Bone marrow cell homing to sites of acute tibial fracture: 89Zr-oxine cell labeling with positron emission tomographic imaging in a mouse model.

Asiedu KO, Ferdousi M, Ton PT, Adler SS, Choyke PL, Sato N.

EJNMMI Res. 2018 Dec 13;8(1):109. doi: 10.1186/s13550-018-0463-8.

38.

Pitfalls on sample preparation for ex vivo imaging of resected cancer tissue using enzyme-activatable fluorescent probes.

Mochida A, Ogata F, Maruoka Y, Nagaya T, Okada R, Inagaki F, Fujimura D, Choyke PL, Kobayashi H.

Oncotarget. 2018 Nov 13;9(89):36039-36047. doi: 10.18632/oncotarget.26320. eCollection 2018 Nov 13.

39.

Activatable Near-Infrared Fluorescence Imaging Using PEGylated Bacteriochlorin-Based Chlorin and BODIPY-Dyads as Probes for Detecting Cancer.

Ogata F, Nagaya T, Maruoka Y, Akhigbe J, Meares A, Lucero MY, Satraitis A, Fujimura D, Okada R, Inagaki F, Choyke PL, Ptaszek M, Kobayashi H.

Bioconjug Chem. 2019 Jan 16;30(1):169-183. doi: 10.1021/acs.bioconjchem.8b00820. Epub 2018 Dec 14.

PMID:
30475591
40.

Sentinel lymph node imaging in urologic oncology.

Mehralivand S, van der Poel H, Winter A, Choyke PL, Pinto PA, Turkbey B.

Transl Androl Urol. 2018 Oct;7(5):887-902. doi: 10.21037/tau.2018.08.23. Review.

41.

Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents.

Czarniecki M, Mena E, Lindenberg L, Cacko M, Harmon S, Radtke JP, Giesel F, Turkbey B, Choyke PL.

Transl Androl Urol. 2018 Oct;7(5):831-843. doi: 10.21037/tau.2018.08.03. Review.

42.

Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer.

Weisman AJ, Harmon SA, Perk TG, Eickhoff J, Choyke PL, Kurdziel KA, Dahut WL, Humm JL, Apolo AB, Larson SM, Morris MJ, Perlman SB, Liu G, Jeraj R.

Prostate Cancer Prostatic Dis. 2019 May;22(2):324-330. doi: 10.1038/s41391-018-0110-5. Epub 2018 Nov 9.

PMID:
30413807
43.

Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine in Solid Tumors.

Young CR, Adler S, Eary JF, Lindenberg ML, Jacobs PM, Collins J, Kummar S, Kurdziel KA, Choyke PL, Mena E.

J Nucl Med. 2019 Apr;60(4):492-496. doi: 10.2967/jnumed.118.216994. Epub 2018 Nov 2.

PMID:
30389817
44.

Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer.

Czarniecki M, Pesapane F, Wood BJ, Choyke PL, Turkbey B.

Transl Androl Urol. 2018 Sep;7(Suppl 4):S453-S461. doi: 10.21037/tau.2018.05.15. Review.

45.

Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET.

Weiss ID, Huff LM, Evbuomwan MO, Xu X, Dang HD, Velez DS, Singh SP, Zhang HH, Gardina PJ, Lee JH, Lindenberg L, Myers TG, Paik CH, Schrump DS, Pittaluga S, Choyke PL, Fojo T, Farber JM.

Oncotarget. 2018 Oct 2;9(77):34641. doi: 10.18632/oncotarget.26214. eCollection 2018 Oct 2.

46.

Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? a multi-center, multi-reader investigation.

Gaur S, Lay N, Harmon SA, Doddakashi S, Mehralivand S, Argun B, Barrett T, Bednarova S, Girometti R, Karaarslan E, Kural AR, Oto A, Purysko AS, Antic T, Magi-Galluzzi C, Saglican Y, Sioletic S, Warren AY, Bittencourt L, Fütterer JJ, Gupta RT, Kabakus I, Law YM, Margolis DJ, Shebel H, Westphalen AC, Wood BJ, Pinto PA, Shih JH, Choyke PL, Summers RM, Turkbey B.

Oncotarget. 2018 Sep 18;9(73):33804-33817. doi: 10.18632/oncotarget.26100. eCollection 2018 Sep 18.

47.

Near infrared photoimmunotherapy using a fiber optic diffuser for treating peritoneal gastric cancer dissemination.

Nagaya T, Okuyama S, Ogata F, Maruoka Y, Choyke PL, Kobayashi H.

Gastric Cancer. 2019 May;22(3):463-472. doi: 10.1007/s10120-018-0871-5. Epub 2018 Aug 31.

PMID:
30171392
48.

Deep dense multi-path neural network for prostate segmentation in magnetic resonance imaging.

To MNN, Vu DQ, Turkbey B, Choyke PL, Kwak JT.

Int J Comput Assist Radiol Surg. 2018 Nov;13(11):1687-1696. doi: 10.1007/s11548-018-1841-4. Epub 2018 Aug 7.

49.

Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.

Bloom JB, Hale GR, Gold SA, Rayn KN, Smith C, Mehralivand S, Czarniecki M, Valera V, Wood BJ, Merino MJ, Choyke PL, Parnes HL, Turkbey B, Pinto PA.

J Urol. 2019 Jan;201(1):84-90. doi: 10.1016/j.juro.2018.07.051.

PMID:
30063928
50.

Quantitative MRI or Machine Learning for Prostate MRI: Which Should You Use?

Choyke PL.

Radiology. 2018 Oct;289(1):138-139. doi: 10.1148/radiol.2018181304. Epub 2018 Jul 31. No abstract available.

PMID:
30063185

Supplemental Content

Loading ...
Support Center